Business Description

AstraZeneca Plc, a holding company, is involved in developing, researching, and manufacturing pharmaceutical products. Its pipeline can be used in the following therapeutic areas: oncology and cardiovascular, renal, metabolism, and respiratory. The company was established in Cambridge, United Kingdom, on June 17, 1992.

Key Financials

Revenue (US$ Mn):

• AstraZeneca Plc’s annual revenue for 2021 was US$ 37,417 Mn, a 40.58% increase from 2020
• The annual revenue generated by AstraZeneca Plc in 2020 was US$ 26,617 Mn
• At a 10.38% increase, AstraZeneca Plc’s annual revenue of US$ 24,384 Mn was indexed in 2019
• AstraZeneca Plc generated total revenue of US$ 22,090 Mn in 2018

Operating Income (US$ Mn):

• US$ -134 Mn was AstraZeneca Plc’s operating income in 2021, a -103.63% decrease from 2020 figures
• AstraZeneca Plc indexed a 23.13% increase in operating incomes from 2019, amounting to US$ 3,694 Mn in 2020
• AstraZeneca Plc generated an operating income of US$ 3,000 Mn in 2019
• An operating income of US$ 1,510 Mn was indexed by Microsoft Corporation in 2018

Net Income (US$ Mn):

• US$ 112 Mn was the net income generated by AstraZeneca Plc in 2021
• AstraZeneca Plc’s net income for 2020 was US$ 3,196 Mn, a 139.4% increase from 2019
• From 2018’s net incomes, AstraZeneca Plc registered a -38.05% decrease in 2019, amounting to US$ 1,335 Mn
• A net income of US$ 2,155 Mn was generated in 2018 by AstraZeneca Plc

Operating Margin %:

• AstraZeneca Plc’s operating margin for 2021 was -0.4%, a -102.88% decrease from 2020
• The operating margin generated by AstraZeneca Plc in 2020 was 14%
• At an 80.88% increase, AstraZeneca Plc’s operating margin of 12% was indexed in 2019
• AstraZeneca Plc generated an operating margin of 7% in 2018

Gross Margin %:

• 67% was AstraZeneca Plc’s gross margin in 2021, a -16.6% decrease from 2020 figures
• AstraZeneca Plc indexed a 0.38% increase in gross margins from 2019, amounting to 80% in 2020
• AstraZeneca Plc generated a gross margin of 80% in 2019
• A gross margin of 78% was indexed by Microsoft Corporation in 2018

SWOT Analysis

Strengths

Significant R&D capabilities and manufacturing and supply resources

AstraZeneca has significant research and development (R&D) capabilities. The company’s R&D activities focus on developing new medicines for the treatment of various diseases. The company’s R&D capabilities include biologic medicines, including immunotherapies and novel delivery devices, oligonucleotides, small molecules, and other emerging drug platforms. As of December 31, 2020, it had 171 projects in its pipeline and 25 new molecular entities (NMEs) in its late-stage pipeline. It operates R&D centers in Gaithersburg, Boston, California, the US; Gothenburg, Sweden; Shanghai, China; Osaka, Japan; Cambridge, Alderley Park, and Macclesfield, the UK.

The company collaborates with academia, patient groups, scientific organizations, industry, governments, and other pharmaceutical companies to bring innovation and develop new medicines to address unmet medical needs. As of December 31, 2020, the company currently has more than 800 collaborations and obtained patent protection in more than 100 countries around the world. In FY2020, the company spent US$5,872 million on R&D, which accounted for 22.1% of the company’s revenue. AstraZeneca’s significant R&D capabilities and manufacturing and supply resources help it in manufacturing its product efficiently that caters to the unmet needs of its large customer base.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data